Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard first-line treatments for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations.
• Acquired resistance to EGFR-TKIs is a significant clinical challenge, limiting long-term patient benefit.
• Immune checkpoint inhibitors (ICIs) have shown promise in various cancers but exhibit limited efficacy in EGFR-mutated NSCLC.

Purpose of the Study:

• To conduct a meta-analysis evaluating the association between programmed death ligand 1 (PD-L1) expression and the clinical benefit of EGFR-TKIs in advanced NSCLC.
• To review the current landscape of immunotherapy for advanced NSCLC patients harboring EGFR mutations.
• To identify potential biomarkers that predict response to ICIs and define patient subgroups who may benefit from immunotherapy.

Main Methods:

• Meta-analysis of studies assessing PD-L1 expression and EGFR-TKI efficacy.
• Comprehensive literature review of immunotherapy clinical trials and real-world data in EGFR-mutated NSCLC.
• Exploration of predictive biomarkers for ICI response in this specific patient population.

Main Results:

• The meta-analysis aims to clarify the relationship between PD-L1 expression levels and the effectiveness of EGFR-TKIs.
• The review will synthesize data on the efficacy of various ICIs in advanced NSCLC with EGFR mutations.
• Identification of potential predictive biomarkers and patient subgroups for immunotherapy is a key objective.

Conclusions:

• Understanding the role of PD-L1 expression may help optimize EGFR-TKI therapy selection.
• Further research into immunotherapy strategies is crucial for improving outcomes in EGFR-mutated NSCLC.
• Identifying predictive biomarkers will enable personalized treatment approaches, potentially expanding the benefit of ICIs in NSCLC.